Practicing Risk Acceptance

When my QA colleagues are afraid of small risks, I want to tell them it’s okay and that they have my support to make a decision that keeps things moving forward. Such conversations always make me think about how we think about the processes for controlling risk in our industry, commonly referred to as “Risk Analysis” and “Risk Management”.

For me, Risk Analysis is the inventory and characterization of what can go wrong. It ends with a big list of things that we should worry about, and therefore leaves the participants in an anxious and uncomfortable state. I strongly believe that avoidance of this anxiety is a main reason why many colleagues don’t engage readily in Risk Analysis processes.

Risk Management picks up where Risk Analysis leaves off. Risk Management selects the most significant risks and defines actions we can take to reduce or eliminate those risks. With a love of action and a pursuit of results, we then implement our plans to manage the risks. The problem here is that, for QA professionals at least, and many like-minded colleagues in other disciplines, we lose sight of the risks that might be acceptable.

Acceptable risks might be those that have little or no impact, or low probability. These items with low risk scores (RPN scores, in FMEA terms) are easy to deal with. These are not the risks I’m talking about.

The other acceptable risks are the risks of NOT acting, and these risks are becoming more prominent as we move into novel therapeutic areas with more pressing needs. These risks can look like:

  • Risk of releasing a product to a patient when there is some quality concern for that batch/lot, especially when that patient is very sick and has a time-sensitive need for the product.
  • Risk of continuing to operate while final risk management CAPAs are not yet implemented.
  • Risk of unknown factors (absence of evidence is not evidence of absence).
  • And many others!

To be fully effective, QA leaders need to be able to: (1) say “no” to unacceptable risks; (2) define and manage risk so that it is reduced to acceptable levels; and (3) move forward when risks are acceptable. This last part is where we really earn our wages… saying “no” is relatively easy. Saying “Yes, if we manage these risks, weigh the situation in full balance, and follow a defined path, then we can move forward” is more difficult. 

But remember, if we want to be fully effective as professionals, the drug we manage must be both safe and effective. Effective means at the patient’s side, when it’s needed. QA has the opportunity and the obligation to guide that process, so safety is assured and effectiveness is maintained to the fullest extent possible. This means that in addition to Risk Analysis and Risk Management, we must also practice careful, wise, and informed Risk Acceptance.


Mark Roache, QxP VP of Cell and Gene Therapies, has spent his 30-plus year career in GXP. Mark was the Chief Quality Officer for AveXis (now Novartis Gene Therapies) at the time of Zolgensma launch. He was previously Senior VP of Quality for KBI (a CDMO with cell-therapy capabilities) and has held other senior Quality roles at Novartis, Merck and Bayer. 

Click here to read Part 1 of Mark’s two-part blog series on “Experience is What You Get Just After You Needed It.”

The Crucial Nexus: Data Integrity in Pharmaceutical Manufacturing

Christine Feaster
May 17, 2024

Pharmaceutical Industry Trends for 2024 So Far

Christine Feaster
April 24, 2024

Decoding the Technical Transfer Process in Biotech Manufacturing

Sarah Boynton
April 23, 2024

Quality Executive Partners - IACET Accreditation

Ken Mead
April 9, 2024

Coaching and Correcting: A Focus on Behavior Over Blame

Sarah Boynton
November 1, 2023

The Importance of Roles and Responsibilities in Biotech Manufacturing & Human Error Prevention

Sarah Boynton
October 26, 2023

Remote cGMP Inspections and AI in Drug Manufacturing

Michelle Fishburne
October 11, 2023

4 Best Practices for Effective Investigation into Deviations

Sarah Boynton
September 19, 2023

The Art of Viral Vector Manufacturing: 4 Essential Controls to Prevent Cross-Contamination

Sarah Boynton
September 13, 2023

Annex 1 – Can we all take a deep breath now?

Vanessa Figueroa
August 24, 2023

In Cell and Gene, Good Science is Necessary, But Not Sufficient

Mark Roache
August 21, 2023

6 Ways To Achieve Manufacturing Audit And Inspection Readiness

Sarah Boynton
August 14, 2023

Experience is What You Get Just After You Needed It, Part 2

Mark Roache
August 10, 2023

Experience is What You Get Just After You Needed It, Part 1

Mark Roache
August 10, 2023

Sterility Assurance Matters to This ONE

Greg Gibb
August 8, 2023

Enhancing Quality and Safety: 3 Essential Human Error Prevention Tools for cGMP Manufacturing

Sarah Boynton
August 3, 2023

Asia-Pacific Happenings: Samsung Bioepis Implements QxP Virtuosi®

Michelle Fishburne
August 2, 2023

CDMOs – Selecting the Right One for Each Manufacturing Stage

Christine Feaster
July 24, 2023

3 Types of Human Error and Potential CAPAs to Prevent Them

Sarah Boynton
July 20, 2023

Drug Shortages: Causes & Solutions

Christine Feaster
July 10, 2023

The 5 Questions You Need to Ask After a Human Error Event Occurs

Sarah Boynton
July 5, 2023

Understanding How Adults Learn

Mike Levitt
June 30, 2023

Annex 1 and Ensuring Filling Technologies Fit the Need

Natasha Howard
June 21, 2023

How to Solve Pharma’s Skilled Workforce Deficit

Jeff Roy
June 20, 2023

ChatGPT Told Me AI is “Imperative” in Pharma Manufacturing

No items found.
June 18, 2023

Get Ready: FDORA’s Unannounced Foreign Inspection Pilot Program is On!

Crystal Mersh
June 6, 2023

Nitrosamines Impurity Challenges

Christine Feaster
June 2, 2023

All You Need to Know About Contamination Control Strategies, Parts 1 and 2

No items found.
June 1, 2023

When is ISO 8 Not ISO 8?

Bob Ferer
May 30, 2023

Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Crystal Mersh
May 24, 2023

Pharmaceutical Quality is NOT a Spectator Sport

Mike Levitt
May 22, 2023

The Six Keys for Effective Deviation Investigators

Mike Levitt
May 18, 2023

There Has to be a Better Way to Train

Tyler DeWitt, Ph.D.
May 15, 2023

Cell and Gene: Article Series on CGT’s Key Drivers

Mark Roache
May 8, 2023

Bacterial Endotoxin Testing is on the Move

Christine Feaster
May 5, 2023

Top 20 Pharma Company Chooses QxP Virtuosi® Platform

Vanessa Figueroa
May 3, 2023

Crystal Clear: Controls Are Not Enough

Crystal Mersh
April 22, 2023

Myth #1: Complying with Regulations and Product Specifications

Brian Duncan
April 20, 2023

Myth #2: Proactively Remediating Bad Inspection Outcomes: What’s the benefit?

Brian Duncan
April 20, 2023

Is it Time to Outsource Internal Auditing?

Mike Levitt
April 18, 2023

Quality is Number One, Even When Trying to Address Supply Chain Issues

Christine Feaster
April 14, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 2

Bob Ferer
April 10, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 1

Bob Ferer
April 10, 2023